Vulvovaginal Candidiasis
Probiotics may increase cure rates for bacterial vaginosis
July 01, 2022
A cocktail of different probiotic species may be more effective than probiotic monotherapies, according to a recent literature review.
Survey investigates incidence and lifetime prevalence rate of VVC in the US
June 21, 2022
Results from this study can help increase understanding of the estimated incidence and lifetime prevalence of VVC in the US.
Berberine promising therapy to treat vulvovaginal candidiasis
June 21, 2022
Vaginal yeast infections were successfully treated with berberine, a biologically active herbal alkaloid, according to a study published in Frontiers in Pharmacology.
Drug treatments show microbiome changes in women with mixed vaginitis
June 21, 2022
A study published in Frontiers in Cellular and Infection Microbiology observed significant vaginal microbiome alterations in patients with bacterial vaginosis (BV) plus vulvovaginal candidiasis (VVC) mixed vaginitis before and after drug treatment.
Scynexis submits sNDA for expanded indication of ibrexafungerp tablets
June 08, 2022
Currently approved for the treatment of vulvovaginal candidiasis (VVC), and if the sNDA is approved, ibrexafungerp (Brexafemme; Scynexis) would be the first and only oral non-azole medication for the prevention of recurrent VVC.
Belgian study finds seasonal variance in Candida infections
May 23, 2022
The research published in the Journal of Clinical Medicine found women were more likely to have infections in the summer.
Ibrexafungerp for treating vulvovaginal candidiasis
May 20, 2022
In June 2021, ibrexafungerp (Brexafemme; Scynexis) became the first drug approved by the U.S. Food and Drug Administration (FDA) in a novel antifungal class in more than 20 years and is now available to treat vulvovaginal candidiasis (VVC).
FDA approves first drug for RVVC
April 29, 2022
The US Food and Drug Administration has approved oteseconazole (Vivjoa; Mycovia Pharmaceuticals) to reduce the incidence of recurrent vulvovaginal candidiasis.
Twice weekly maintenance therapy ideal for recurrent yeast infections
April 22, 2022
Vulvovaginal candidiasis (VVC)—commonly known as a yeast infection—is a problem many women face at some point. About half of all women have had at least 1 of these infections clinical diagnosed, and between 6% and 10% are believed to develop a recurrent form of this condition with 3 to 4 or more episodes in a single year, according to a new report.